Cargando…
Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma
Natural Killer T cells (NKT cells) are emerging as critical regulators of pro- and anti-tumor immunity, both at baseline and in therapeutic settings. While type I NKT cells can promote anti-tumor immunity, their activity in the tumor microenvironment may be limited by negative regulators such as inh...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877613/ https://www.ncbi.nlm.nih.gov/pubmed/29518903 http://dx.doi.org/10.3390/ijms19030752 |
_version_ | 1783310732106924032 |
---|---|
author | Sekar, Divya Govene, Luisa del Río, María-Luisa Sirait-Fischer, Evelyn Fink, Annika F. Brüne, Bernhard Rodriguez-Barbosa, José I. Weigert, Andreas |
author_facet | Sekar, Divya Govene, Luisa del Río, María-Luisa Sirait-Fischer, Evelyn Fink, Annika F. Brüne, Bernhard Rodriguez-Barbosa, José I. Weigert, Andreas |
author_sort | Sekar, Divya |
collection | PubMed |
description | Natural Killer T cells (NKT cells) are emerging as critical regulators of pro- and anti-tumor immunity, both at baseline and in therapeutic settings. While type I NKT cells can promote anti-tumor immunity, their activity in the tumor microenvironment may be limited by negative regulators such as inhibitory immune checkpoints. We observed dominant expression of B- and T-lymphocyte attenuator (BTLA) on type I NKT cells in polyoma middle T oncogene-driven (PyMT) murine autochthonous mammary tumors. Other immune checkpoint receptors, such as programmed cell death 1 (PD-1) were equally distributed among T cell populations. Interference with BTLA using neutralizing antibodies limited tumor growth and pulmonary metastasis in the PyMT model in a therapeutic setting, correlating with an increase in type I NKT cells and expression of cytotoxic marker genes. While therapeutic application of an anti-PD-1 antibody increased the number of CD8+ cytotoxic T cells and elevated IL-12 expression, tumor control was not established. Expression of ZBTB16, the lineage-determining transcription factor of type I NKT cells, was correlated with a favorable patient prognosis in the METABRIC dataset, and BTLA levels were instrumental to further distinguish prognosis in patents with high ZBTB16 expression. Taken together, these data support a role of BTLA on type I NKT cells in limiting anti-tumor immunity. |
format | Online Article Text |
id | pubmed-5877613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58776132018-04-09 Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma Sekar, Divya Govene, Luisa del Río, María-Luisa Sirait-Fischer, Evelyn Fink, Annika F. Brüne, Bernhard Rodriguez-Barbosa, José I. Weigert, Andreas Int J Mol Sci Article Natural Killer T cells (NKT cells) are emerging as critical regulators of pro- and anti-tumor immunity, both at baseline and in therapeutic settings. While type I NKT cells can promote anti-tumor immunity, their activity in the tumor microenvironment may be limited by negative regulators such as inhibitory immune checkpoints. We observed dominant expression of B- and T-lymphocyte attenuator (BTLA) on type I NKT cells in polyoma middle T oncogene-driven (PyMT) murine autochthonous mammary tumors. Other immune checkpoint receptors, such as programmed cell death 1 (PD-1) were equally distributed among T cell populations. Interference with BTLA using neutralizing antibodies limited tumor growth and pulmonary metastasis in the PyMT model in a therapeutic setting, correlating with an increase in type I NKT cells and expression of cytotoxic marker genes. While therapeutic application of an anti-PD-1 antibody increased the number of CD8+ cytotoxic T cells and elevated IL-12 expression, tumor control was not established. Expression of ZBTB16, the lineage-determining transcription factor of type I NKT cells, was correlated with a favorable patient prognosis in the METABRIC dataset, and BTLA levels were instrumental to further distinguish prognosis in patents with high ZBTB16 expression. Taken together, these data support a role of BTLA on type I NKT cells in limiting anti-tumor immunity. MDPI 2018-03-07 /pmc/articles/PMC5877613/ /pubmed/29518903 http://dx.doi.org/10.3390/ijms19030752 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sekar, Divya Govene, Luisa del Río, María-Luisa Sirait-Fischer, Evelyn Fink, Annika F. Brüne, Bernhard Rodriguez-Barbosa, José I. Weigert, Andreas Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma |
title | Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma |
title_full | Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma |
title_fullStr | Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma |
title_full_unstemmed | Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma |
title_short | Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma |
title_sort | downregulation of btla on nkt cells promotes tumor immune control in a mouse model of mammary carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877613/ https://www.ncbi.nlm.nih.gov/pubmed/29518903 http://dx.doi.org/10.3390/ijms19030752 |
work_keys_str_mv | AT sekardivya downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT goveneluisa downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT delriomarialuisa downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT siraitfischerevelyn downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT finkannikaf downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT brunebernhard downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT rodriguezbarbosajosei downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma AT weigertandreas downregulationofbtlaonnktcellspromotestumorimmunecontrolinamousemodelofmammarycarcinoma |